The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Please sign up for SocialPicks site access - it's free!

 Allstate Corp. The  (ALL) Trade Now »     Rate ALL  -  Discuss ALL  -  Add to Watch List         Graphic_subscribe

       Sector: Financial  >  Industry: Insurance (Prop. & Casualty)
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
32.0%
Top:
0.0%
Rate ALL:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

ALL: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

Clolar Decision Aside, Genzyme's Still a Near-Term Sell
<>On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to follow this recommendation, however, it usually does, which suggests that the agency will not likely approve this label expansion in December of this year. This announcement is not surprising given that the published FDA briefing documents indicated concern over the lack of a control-arm in Genzyme's pivotal trial to support this label expansion, along with other questions related...
By  trackseekingalpha   (-11.17%  risk: aggressive)  09/02/09 Comment


Clolar Decision Aside, Genzyme's Still a Near-Term Sell
<>On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to follow this recommendation, however, it usually does, which suggests that the agency will not likely approve this label expansion in December of this year. This announcement is not surprising given that the published FDA briefing documents indicated concern over the lack of a control-arm in Genzyme's pivotal trial to support this label expansion, along with other questions related...
By  trackseekingalpha   (-11.17%  risk: aggressive)  09/02/09 Comment


Genzyme: Near Term Sell, Long Term Buy
<>On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to follow this recommendation, however, it usually does, which suggests that the agency will not likely approve this label expansion in December of this year. This announcement is not surprising given that the published FDA briefing documents indicated concern over the lack of a control-arm in Genzyme's pivotal trial to support this label expansion, along with other questions related...
By  trackseekingalpha   (-11.17%  risk: aggressive)  09/02/09 Comment


Genzyme: Near Term Sell, Long Term Buy
<>On Tuesday morning, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 9 to 3 against the label expansion of Genzyme's (GENZ) leukemia drug, Clolar, in acute myeloid leukemia (AML). The FDA does not have to follow this recommendation, however, it usually does, which suggests that the agency will not likely approve this label expansion in December of this year. This announcement is not surprising given that the published FDA briefing documents indicated concern over the lack of a control-arm in Genzyme's pivotal trial to support this label expansion, along with other questions related...
By  trackseekingalpha   (-11.17%  risk: aggressive)  09/02/09 Comment


Analyst upgrades, downgrades and initiations: ALL, CMG, GRMN, IP, VRSN ...

Filed under: Analyst reports, Analyst upgrades and downgrades, Analyst initiations

Analyst upgrades:

<>
  • Goldman said International Paper (NYSE: IP) is its top pick in the group citing leverage to early cycle containerboard. The firm upgraded shares to Conviction Buy from Buy and has a $26 target on the stock.
  • Morgan Keegan upgraded Healthcare Realty Trust (NYSE: HR) to Outperform from Market Perform citing valuation and better-than-expected Q2 results.
    • <>William Blair upgraded Harbin Electric (NASDAQ: HRBN) to Outperform from Market Perform as it believes the Chinese economy is likely ...
    By  Blogging Stocks    08/12/09 Comment



    ROCK-STAR INVESTORS
    Rank Name Sharpe Ratio Avg Return Followers
    1 noshoes 21.10 +34.25% 381
    2 Gerald Greene 18.14 +72.34% 210
    3 stockmarketfunding.com 17.66 +25.65% 55
    4 akiralegrand 13.47 +14.32% 61
    5 anup2104 12.13 +76.91% 39


    POPULAR STOCKS
    Symbol Company Name Sentiment
    MCD McDonald's Corp.
    C Citigroup Inc
    KO The CocaCola Company
    AMD Advanced Micro Devices Inc
    MO Altria Group Inc
    IBM International Business Machines Corp

    TODAY'S HEADLINES

    TODAY'S TOP PICKS

    		 

    StreetInsider.com on ALL

    Visit streetinsider.com


    Discussion Wall + Add  
    bpmiller1   (+168.40%  risk: conservative)
    They all follow SPY - Heres a simple method I use for to gauge where a stock will go using SPY . SPY is the bandleader with more volume 2-3x than any other stock (except for...
    +   4 replies


    More Resources

    Graphic_arrow1 About Allstate Corp. The - Answers.com

    Graphic_arrow1 Historical Prices - Yahoo

    Graphic_arrow1 Message Boards - BoardCentral.com

    Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




    		IN THE PRESS
    Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch